Cargando…

1097. A Prospective Evaluation of SARS-CoV-2 Shedding and Evolution in Immunocompromised Hosts During the Omicron Period — IVY Network, 5 U.S. States, April 11, 2022 – February 1, 2023

BACKGROUND: Prolonged SARS-CoV-2 infections in immunocompromised hosts may predict or source the emergence of highly mutated variants of concern. The types of immunosuppression placing patients at highest risk for prolonged infection and associated intra-host viral evolution remain unclear. [Figure:...

Descripción completa

Detalles Bibliográficos
Autores principales: Raglow, Zoe M, Surie, Diya, Chappell, James, Zhu, Yuwei, Martin, Emily T, Kwon, Jennie H, Frosch, Anne, Mohamed, Amira, Gilbert, Julie, Bendall, Emily E, Bahr, Auden, Halasa, Natasha B, Talbot, H Keipp, Grijalva, Carlos G, Baughman, Adrienne, Womack, Kelsey N, Johnson, Cassandra, Swan, Sydney A, Burroughs, Ashley, Koumans, Emilia, McMorrow, Meredith L, Harcourt, Jennifer L, Atherton, Lydia J, Thornburg, Natalie J, Self, Wesley, Lauring, Adam S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678486/
http://dx.doi.org/10.1093/ofid/ofad500.070
_version_ 1785150373188599808
author Raglow, Zoe M
Surie, Diya
Chappell, James
Zhu, Yuwei
Martin, Emily T
Kwon, Jennie H
Frosch, Anne
Mohamed, Amira
Gilbert, Julie
Bendall, Emily E
Bahr, Auden
Halasa, Natasha B
Talbot, H Keipp
Grijalva, Carlos G
Baughman, Adrienne
Womack, Kelsey N
Johnson, Cassandra
Swan, Sydney A
Burroughs, Ashley
Koumans, Emilia
McMorrow, Meredith L
Harcourt, Jennifer L
Atherton, Lydia J
Thornburg, Natalie J
Self, Wesley
Lauring, Adam S
author_facet Raglow, Zoe M
Surie, Diya
Chappell, James
Zhu, Yuwei
Martin, Emily T
Kwon, Jennie H
Frosch, Anne
Mohamed, Amira
Gilbert, Julie
Bendall, Emily E
Bahr, Auden
Halasa, Natasha B
Talbot, H Keipp
Grijalva, Carlos G
Baughman, Adrienne
Womack, Kelsey N
Johnson, Cassandra
Swan, Sydney A
Burroughs, Ashley
Koumans, Emilia
McMorrow, Meredith L
Harcourt, Jennifer L
Atherton, Lydia J
Thornburg, Natalie J
Self, Wesley
Lauring, Adam S
author_sort Raglow, Zoe M
collection PubMed
description BACKGROUND: Prolonged SARS-CoV-2 infections in immunocompromised hosts may predict or source the emergence of highly mutated variants of concern. The types of immunosuppression placing patients at highest risk for prolonged infection and associated intra-host viral evolution remain unclear. [Figure: see text] [Figure: see text] METHODS: Adults aged ≥18 years were enrolled and followed at 5 hospitals in the Investigating Respiratory Viruses in the Acutely Ill (IVY) Network from 4/11/2022 – 2/1/2023. Eligible patients were SARS-CoV-2-positive by RT-qPCR in the previous 14 days and had an immunocompromising condition, including malignancy, solid organ or hematopoietic stem cell transplant (SOT/HSCT), autoimmune/autoinflammatory condition on immunosuppression, AIDS, or primary immunodeficiency. Nasal specimens were collected and tested by RT-qPCR every 2–4 weeks until negative in 2 consecutive specimens. All specimens underwent viral culture and whole genome sequencing. A Cox proportional hazards model was used to assess factors associated with prolonged infection. [Figure: see text] RESULTS: 150 patients were enrolled with the following conditions: B cell malignancy or anti-B cell therapy (n=18), SOT/HSCT (n=59), AIDS (n=5), non-B cell malignancy (n=23), and autoimmune/autoinflammatory (n=45, Table 1). 37 (25%) were RT-qPCR-positive and 11 (7%) were culture-positive ≥21 days after infection onset. Patients with B cell dysfunction had prolonged infection compared to those with autoimmune/autoinflammatory conditions (aHR 0.28, 95% CI 0.14–0.58) (Figures 1, 2). The within-host evolutionary rate was similar in prolonged (≥ 21 days) and shorter (< 21 days) infections (Figure 3). Consensus spike mutations were identified in 4 individuals who were RT-qPCR-positive ≥ 56 days; 68% were in the receptor-binding domain (RBD) (Figures 4, 5). The common spike mutations in this analysis were rare (< 2%) in global circulation. [Figure: see text] [Figure: see text] [Figure: see text] CONCLUSION: In this prospective cohort of immunocompromised patients during the Omicron variant period, prolonged SARS-CoV-2 infections were uncommon. While the within-host evolutionary rates are similar between prolonged and shorter infections, individuals with infections lasting ≥ 56 days accumulated mutations in the spike protein. These appear distinct from those seen globally. [Figure: see text] Bisected squares indicate more than one genomic mutation produced the same amino acid mutation. RBD is highlighted in gray. DISCLOSURES: Emily T. Martin, PhD, MPH, Merck: Grant/Research Support Natasha B. Halasa, MD, MPH, Merck: Grant/Research Support|Quidell: Grant/Research Support|Quidell: donation of kits|Sanofi: Grant/Research Support|Sanofi: vaccine support Carlos G. Grijalva, MD, MPH, AHRQ: Grant/Research Support|CDC: Grant/Research Support|FDA: Grant/Research Support|Merck: Advisor/Consultant|NIH: Grant/Research Support|Syneos Health: Grant/Research Support Adam S. Lauring, MD, PhD, Roche: Advisor/Consultant|Sanofi: Advisor/Consultant
format Online
Article
Text
id pubmed-10678486
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106784862023-11-27 1097. A Prospective Evaluation of SARS-CoV-2 Shedding and Evolution in Immunocompromised Hosts During the Omicron Period — IVY Network, 5 U.S. States, April 11, 2022 – February 1, 2023 Raglow, Zoe M Surie, Diya Chappell, James Zhu, Yuwei Martin, Emily T Kwon, Jennie H Frosch, Anne Mohamed, Amira Gilbert, Julie Bendall, Emily E Bahr, Auden Halasa, Natasha B Talbot, H Keipp Grijalva, Carlos G Baughman, Adrienne Womack, Kelsey N Johnson, Cassandra Swan, Sydney A Burroughs, Ashley Koumans, Emilia McMorrow, Meredith L Harcourt, Jennifer L Atherton, Lydia J Thornburg, Natalie J Self, Wesley Lauring, Adam S Open Forum Infect Dis Abstract BACKGROUND: Prolonged SARS-CoV-2 infections in immunocompromised hosts may predict or source the emergence of highly mutated variants of concern. The types of immunosuppression placing patients at highest risk for prolonged infection and associated intra-host viral evolution remain unclear. [Figure: see text] [Figure: see text] METHODS: Adults aged ≥18 years were enrolled and followed at 5 hospitals in the Investigating Respiratory Viruses in the Acutely Ill (IVY) Network from 4/11/2022 – 2/1/2023. Eligible patients were SARS-CoV-2-positive by RT-qPCR in the previous 14 days and had an immunocompromising condition, including malignancy, solid organ or hematopoietic stem cell transplant (SOT/HSCT), autoimmune/autoinflammatory condition on immunosuppression, AIDS, or primary immunodeficiency. Nasal specimens were collected and tested by RT-qPCR every 2–4 weeks until negative in 2 consecutive specimens. All specimens underwent viral culture and whole genome sequencing. A Cox proportional hazards model was used to assess factors associated with prolonged infection. [Figure: see text] RESULTS: 150 patients were enrolled with the following conditions: B cell malignancy or anti-B cell therapy (n=18), SOT/HSCT (n=59), AIDS (n=5), non-B cell malignancy (n=23), and autoimmune/autoinflammatory (n=45, Table 1). 37 (25%) were RT-qPCR-positive and 11 (7%) were culture-positive ≥21 days after infection onset. Patients with B cell dysfunction had prolonged infection compared to those with autoimmune/autoinflammatory conditions (aHR 0.28, 95% CI 0.14–0.58) (Figures 1, 2). The within-host evolutionary rate was similar in prolonged (≥ 21 days) and shorter (< 21 days) infections (Figure 3). Consensus spike mutations were identified in 4 individuals who were RT-qPCR-positive ≥ 56 days; 68% were in the receptor-binding domain (RBD) (Figures 4, 5). The common spike mutations in this analysis were rare (< 2%) in global circulation. [Figure: see text] [Figure: see text] [Figure: see text] CONCLUSION: In this prospective cohort of immunocompromised patients during the Omicron variant period, prolonged SARS-CoV-2 infections were uncommon. While the within-host evolutionary rates are similar between prolonged and shorter infections, individuals with infections lasting ≥ 56 days accumulated mutations in the spike protein. These appear distinct from those seen globally. [Figure: see text] Bisected squares indicate more than one genomic mutation produced the same amino acid mutation. RBD is highlighted in gray. DISCLOSURES: Emily T. Martin, PhD, MPH, Merck: Grant/Research Support Natasha B. Halasa, MD, MPH, Merck: Grant/Research Support|Quidell: Grant/Research Support|Quidell: donation of kits|Sanofi: Grant/Research Support|Sanofi: vaccine support Carlos G. Grijalva, MD, MPH, AHRQ: Grant/Research Support|CDC: Grant/Research Support|FDA: Grant/Research Support|Merck: Advisor/Consultant|NIH: Grant/Research Support|Syneos Health: Grant/Research Support Adam S. Lauring, MD, PhD, Roche: Advisor/Consultant|Sanofi: Advisor/Consultant Oxford University Press 2023-11-27 /pmc/articles/PMC10678486/ http://dx.doi.org/10.1093/ofid/ofad500.070 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Raglow, Zoe M
Surie, Diya
Chappell, James
Zhu, Yuwei
Martin, Emily T
Kwon, Jennie H
Frosch, Anne
Mohamed, Amira
Gilbert, Julie
Bendall, Emily E
Bahr, Auden
Halasa, Natasha B
Talbot, H Keipp
Grijalva, Carlos G
Baughman, Adrienne
Womack, Kelsey N
Johnson, Cassandra
Swan, Sydney A
Burroughs, Ashley
Koumans, Emilia
McMorrow, Meredith L
Harcourt, Jennifer L
Atherton, Lydia J
Thornburg, Natalie J
Self, Wesley
Lauring, Adam S
1097. A Prospective Evaluation of SARS-CoV-2 Shedding and Evolution in Immunocompromised Hosts During the Omicron Period — IVY Network, 5 U.S. States, April 11, 2022 – February 1, 2023
title 1097. A Prospective Evaluation of SARS-CoV-2 Shedding and Evolution in Immunocompromised Hosts During the Omicron Period — IVY Network, 5 U.S. States, April 11, 2022 – February 1, 2023
title_full 1097. A Prospective Evaluation of SARS-CoV-2 Shedding and Evolution in Immunocompromised Hosts During the Omicron Period — IVY Network, 5 U.S. States, April 11, 2022 – February 1, 2023
title_fullStr 1097. A Prospective Evaluation of SARS-CoV-2 Shedding and Evolution in Immunocompromised Hosts During the Omicron Period — IVY Network, 5 U.S. States, April 11, 2022 – February 1, 2023
title_full_unstemmed 1097. A Prospective Evaluation of SARS-CoV-2 Shedding and Evolution in Immunocompromised Hosts During the Omicron Period — IVY Network, 5 U.S. States, April 11, 2022 – February 1, 2023
title_short 1097. A Prospective Evaluation of SARS-CoV-2 Shedding and Evolution in Immunocompromised Hosts During the Omicron Period — IVY Network, 5 U.S. States, April 11, 2022 – February 1, 2023
title_sort 1097. a prospective evaluation of sars-cov-2 shedding and evolution in immunocompromised hosts during the omicron period — ivy network, 5 u.s. states, april 11, 2022 – february 1, 2023
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678486/
http://dx.doi.org/10.1093/ofid/ofad500.070
work_keys_str_mv AT raglowzoem 1097aprospectiveevaluationofsarscov2sheddingandevolutioninimmunocompromisedhostsduringtheomicronperiodivynetwork5usstatesapril112022february12023
AT suriediya 1097aprospectiveevaluationofsarscov2sheddingandevolutioninimmunocompromisedhostsduringtheomicronperiodivynetwork5usstatesapril112022february12023
AT chappelljames 1097aprospectiveevaluationofsarscov2sheddingandevolutioninimmunocompromisedhostsduringtheomicronperiodivynetwork5usstatesapril112022february12023
AT zhuyuwei 1097aprospectiveevaluationofsarscov2sheddingandevolutioninimmunocompromisedhostsduringtheomicronperiodivynetwork5usstatesapril112022february12023
AT martinemilyt 1097aprospectiveevaluationofsarscov2sheddingandevolutioninimmunocompromisedhostsduringtheomicronperiodivynetwork5usstatesapril112022february12023
AT kwonjennieh 1097aprospectiveevaluationofsarscov2sheddingandevolutioninimmunocompromisedhostsduringtheomicronperiodivynetwork5usstatesapril112022february12023
AT froschanne 1097aprospectiveevaluationofsarscov2sheddingandevolutioninimmunocompromisedhostsduringtheomicronperiodivynetwork5usstatesapril112022february12023
AT mohamedamira 1097aprospectiveevaluationofsarscov2sheddingandevolutioninimmunocompromisedhostsduringtheomicronperiodivynetwork5usstatesapril112022february12023
AT gilbertjulie 1097aprospectiveevaluationofsarscov2sheddingandevolutioninimmunocompromisedhostsduringtheomicronperiodivynetwork5usstatesapril112022february12023
AT bendallemilye 1097aprospectiveevaluationofsarscov2sheddingandevolutioninimmunocompromisedhostsduringtheomicronperiodivynetwork5usstatesapril112022february12023
AT bahrauden 1097aprospectiveevaluationofsarscov2sheddingandevolutioninimmunocompromisedhostsduringtheomicronperiodivynetwork5usstatesapril112022february12023
AT halasanatashab 1097aprospectiveevaluationofsarscov2sheddingandevolutioninimmunocompromisedhostsduringtheomicronperiodivynetwork5usstatesapril112022february12023
AT talbothkeipp 1097aprospectiveevaluationofsarscov2sheddingandevolutioninimmunocompromisedhostsduringtheomicronperiodivynetwork5usstatesapril112022february12023
AT grijalvacarlosg 1097aprospectiveevaluationofsarscov2sheddingandevolutioninimmunocompromisedhostsduringtheomicronperiodivynetwork5usstatesapril112022february12023
AT baughmanadrienne 1097aprospectiveevaluationofsarscov2sheddingandevolutioninimmunocompromisedhostsduringtheomicronperiodivynetwork5usstatesapril112022february12023
AT womackkelseyn 1097aprospectiveevaluationofsarscov2sheddingandevolutioninimmunocompromisedhostsduringtheomicronperiodivynetwork5usstatesapril112022february12023
AT johnsoncassandra 1097aprospectiveevaluationofsarscov2sheddingandevolutioninimmunocompromisedhostsduringtheomicronperiodivynetwork5usstatesapril112022february12023
AT swansydneya 1097aprospectiveevaluationofsarscov2sheddingandevolutioninimmunocompromisedhostsduringtheomicronperiodivynetwork5usstatesapril112022february12023
AT burroughsashley 1097aprospectiveevaluationofsarscov2sheddingandevolutioninimmunocompromisedhostsduringtheomicronperiodivynetwork5usstatesapril112022february12023
AT koumansemilia 1097aprospectiveevaluationofsarscov2sheddingandevolutioninimmunocompromisedhostsduringtheomicronperiodivynetwork5usstatesapril112022february12023
AT mcmorrowmeredithl 1097aprospectiveevaluationofsarscov2sheddingandevolutioninimmunocompromisedhostsduringtheomicronperiodivynetwork5usstatesapril112022february12023
AT harcourtjenniferl 1097aprospectiveevaluationofsarscov2sheddingandevolutioninimmunocompromisedhostsduringtheomicronperiodivynetwork5usstatesapril112022february12023
AT athertonlydiaj 1097aprospectiveevaluationofsarscov2sheddingandevolutioninimmunocompromisedhostsduringtheomicronperiodivynetwork5usstatesapril112022february12023
AT thornburgnataliej 1097aprospectiveevaluationofsarscov2sheddingandevolutioninimmunocompromisedhostsduringtheomicronperiodivynetwork5usstatesapril112022february12023
AT selfwesley 1097aprospectiveevaluationofsarscov2sheddingandevolutioninimmunocompromisedhostsduringtheomicronperiodivynetwork5usstatesapril112022february12023
AT lauringadams 1097aprospectiveevaluationofsarscov2sheddingandevolutioninimmunocompromisedhostsduringtheomicronperiodivynetwork5usstatesapril112022february12023